Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data

Fig. 2

IPD-only and IPD and aggregate data networks for (a) mean change in BCVA (continuous outcome) and (b) gain/loss of ≥10 and ≥ 15 ETDRS letters (binary outcomes). 2q8, every 8 weeks; BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IPD, individual patient-level data; IVTA, intravitreal triamcinolone acetonide; IVT-AFL, intravitreal aflibercept; PRN, as-needed; q4, every 4 weeks; T&E, treat-and-extend. aRESPOND did not provide data for letter losses. Note: outcomes for ranibizumab 0.3 mg (US dose), intravitreal triamcinolone acetonide and bevacizumab are not reported

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us